开云app官网登录入口网页版-官方正版

#Csk#

97篇内容 | 2076人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1777311, encodeId=b9b81e773110c, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=JCI Insight：枯草杆菌前蛋白转换酶9(PCSK9)是银屑病的新的易感基因, objectType=article, longId=735903, objectId=98d9e359036b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98d9e359036b, replyNumber=0, likeNumber=132, createdTime=2023-01-06, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98d9e359036b, moduleTitle=JCI Insight：枯草杆菌前蛋白转换酶9(PCSK9)是银屑病的新的易感基因, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=98d9e359036b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777310, encodeId=554a1e77310d5, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=JACC：长期抑制PCSK9和HMGCR对神经认知功能的影响, objectType=article, longId=735380, objectId=2f7ee35380bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f7ee35380bb, replyNumber=0, likeNumber=114, createdTime=2023-06-13, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f7ee35380bb, moduleTitle=JACC：长期抑制PCSK9和HMGCR对神经认知功能的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2f7ee35380bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777308, encodeId=0ca61e7730852, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=Nat Commun：多喝咖啡能续命的分子机制：咖啡因降低PCSK9，清除坏胆固醇，预防心血管疾病, objectType=article, longId=299192, objectId=011f29919231, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=011f29919231, replyNumber=0, likeNumber=69, createdTime=2022-06-11, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=011f29919231, moduleTitle=Nat Commun：多喝咖啡能续命的分子机制：咖啡因降低PCSK9，清除坏胆固醇，预防心血管疾病, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=011f29919231)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777306, encodeId=2d421e7730666, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=Nutrients：在慢性他汀类药物治疗患者中，补充二十八烷醇会影响PCSK9水平并恢复其与 LDL-C的生理关系, objectType=article, longId=218804, objectId=951221880465, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=951221880465, replyNumber=0, likeNumber=74, createdTime=2022-04-16, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=951221880465, moduleTitle=Nutrients：在慢性他汀类药物治疗患者中，补充二十八烷醇会影响PCSK9水平并恢复其与 LDL-C的生理关系, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=951221880465)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777309, encodeId=c0ca1e7730922, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=Front Pharmacol：不同PCSK9抑制剂，哪个降脂力量更强？, objectType=article, longId=726544, objectId=1e53e265444e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e53e265444e, replyNumber=0, likeNumber=109, createdTime=2022-08-06, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e53e265444e, moduleTitle=Front Pharmacol：不同PCSK9抑制剂，哪个降脂力量更强？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1e53e265444e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777307, encodeId=3e5d1e77307e8, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=AHA 2021丨MK-0616（一种口服PCSK9抑制剂）的临床安全性、药代动力学和降低低密度脂蛋白胆固醇的疗效, objectType=article, longId=220423, objectId=65e722042367, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65e722042367, replyNumber=0, likeNumber=89, createdTime=2022-03-05, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65e722042367, moduleTitle=AHA 2021丨MK-0616（一种口服PCSK9抑制剂）的临床安全性、药代动力学和降低低密度脂蛋白胆固醇的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=65e722042367)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777305, encodeId=54eb1e773052d, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=JACC：高脂血症患者的福音！这些人能从强大的新型降脂药PCSK9抑制剂中获益！ , objectType=article, longId=215102, objectId=32d5215102e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32d5215102e2, replyNumber=0, likeNumber=82, createdTime=2021-08-18, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32d5215102e2, moduleTitle=JACC：高脂血症患者的福音！这些人能从强大的新型降脂药PCSK9抑制剂中获益！ , moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=32d5215102e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777304, encodeId=7ac91e7730480, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=J Clin Med：一项初步研究：PCSK9抑制剂依洛尤单抗对心血管疾病高危患者醛固酮分泌的影响, objectType=article, longId=213902, objectId=47232139022c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47232139022c, replyNumber=0, likeNumber=70, createdTime=2022-06-02, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47232139022c, moduleTitle=J Clin Med：一项初步研究：PCSK9抑制剂依洛尤单抗对心血管疾病高危患者醛固酮分泌的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=47232139022c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777301, encodeId=4a041e773018f, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=JAHA：动脉粥样硬化疾病患者PCSK9抑制剂使用情况, objectType=article, longId=210568, objectId=111721056885, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=111721056885, replyNumber=0, likeNumber=65, createdTime=2021-09-12, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=111721056885, moduleTitle=JAHA：动脉粥样硬化疾病患者PCSK9抑制剂使用情况, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=111721056885)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777303, encodeId=04861e773030d, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=防控有道，风险管理丨黄幸涛：早发冠心病患者的PCSK9i应用经验, objectType=article, longId=213650, objectId=7853213650cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7853213650cb, replyNumber=0, likeNumber=105, createdTime=2021-08-01, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7853213650cb, moduleTitle=防控有道，风险管理丨黄幸涛：早发冠心病患者的PCSK9i应用经验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7853213650cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777302, encodeId=3b381e773029d, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=防控有道，风险管理丨廉羚：降脂唯“安”：PCSK9i改善椎动脉重度狭窄, objectType=article, longId=210369, objectId=5152210369bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5152210369bb, replyNumber=0, likeNumber=67, createdTime=2021-06-28, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5152210369bb, moduleTitle=防控有道，风险管理丨廉羚：降脂唯“安”：PCSK9i改善椎动脉重度狭窄, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5152210369bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777295, encodeId=0b081e7729521, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=J INTERN MED：PCSK9与感染性休克患者死亡率相关, objectType=article, longId=197829, objectId=111019e82913, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=111019e82913, replyNumber=0, likeNumber=75, createdTime=2020-07-25, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=111019e82913, moduleTitle=J INTERN MED：PCSK9与感染性休克患者死亡率相关, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=111019e82913)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777296, encodeId=255f1e77296e1, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=专家访谈:生命至上——PCSK9抑制剂值得被更多ACS患者使用, objectType=article, longId=201145, objectId=331b20114592, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=331b20114592, replyNumber=0, likeNumber=87, createdTime=2021-03-13, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=331b20114592, moduleTitle=专家访谈:生命至上——PCSK9抑制剂值得被更多ACS患者使用, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=331b20114592)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777299, encodeId=80631e7729992, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=JAMA Cardiology：与他汀类药物和依折麦布相比，PCSK9抑制剂降低LDL-C的效果更显著, objectType=article, longId=203418, objectId=ecf82034184f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ecf82034184f, replyNumber=0, likeNumber=70, createdTime=2021-08-01, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ecf82034184f, moduleTitle=JAMA Cardiology：与他汀类药物和依折麦布相比，PCSK9抑制剂降低LDL-C的效果更显著, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ecf82034184f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777292, encodeId=6c751e772924c, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=JAHA：PCSK9抑制剂对其他降脂药物的使用情况的影响, objectType=article, longId=192961, objectId=37e419296119, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37e419296119, replyNumber=0, likeNumber=99, createdTime=2020-07-28, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37e419296119, moduleTitle=JAHA：PCSK9抑制剂对其他降脂药物的使用情况的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=37e419296119)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777297, encodeId=f5971e772978b, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=HFSA 2020：PCSK9抑制剂有效降低心脏移植后的胆固醇水平, objectType=article, longId=202055, objectId=95c92020558c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95c92020558c, replyNumber=0, likeNumber=101, createdTime=2020-11-21, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95c92020558c, moduleTitle=HFSA 2020：PCSK9抑制剂有效降低心脏移植后的胆固醇水平, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=95c92020558c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777298, encodeId=c3c11e772987b, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=降脂神药！一年给药2次，药效持续17个月，诺华的siPCSK9疗法inclisiran获得欧洲CHMP的正面评价, objectType=article, longId=202221, objectId=a2c720222179, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2c720222179, replyNumber=0, likeNumber=102, createdTime=2021-06-27, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2c720222179, moduleTitle=降脂神药！一年给药2次，药效持续17个月，诺华的siPCSK9疗法inclisiran获得欧洲CHMP的正面评价, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a2c720222179)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777300, encodeId=aaf21e7730087, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=无论年龄和性别，诺华靶向PCSK9的siRNA疗法均可在17个月内持续有效降低LDL-C, objectType=article, longId=203468, objectId=f49f20346875, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f49f20346875, replyNumber=0, likeNumber=73, createdTime=2021-06-08, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f49f20346875, moduleTitle=无论年龄和性别，诺华靶向PCSK9的siRNA疗法均可在17个月内持续有效降低LDL-C, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f49f20346875)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777288, encodeId=67f61e7728837, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=诺华与英国NHS联合，以快速推进胆固醇PCSK9的基因干扰药物inclisiran, objectType=article, longId=186391, objectId=6e90186391ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e90186391ad, replyNumber=0, likeNumber=112, createdTime=2020-11-10, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e90186391ad, moduleTitle=诺华与英国NHS联合，以快速推进胆固醇PCSK9的基因干扰药物inclisiran, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6e90186391ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777294, encodeId=d8ee1e77294a2, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=JAHA：PCSK9抑制剂可改善HIV携带者冠脉健康, objectType=article, longId=197806, objectId=93af19e80665, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93af19e80665, replyNumber=0, likeNumber=101, createdTime=2020-11-06, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93af19e80665, moduleTitle=JAHA：PCSK9抑制剂可改善HIV携带者冠脉健康, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=93af19e80665)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

Csk

2020-05-29

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

JCI Insight：枯草杆菌前蛋白转换酶9(PCSK9)是银屑病的新的易感基因

2023-01-06

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

JACC：长期抑制PCSK9和HMGCR对神经认知功能的影响

2023-06-13

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

Nat Commun：多喝咖啡能续命的分子机制：咖啡因降低PCSK9，清除坏胆固醇，预防心血管疾病

2022-06-11

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

Nutrients：在慢性他汀类药物治疗患者中，补充二十八烷醇会影响PCSK9水平并恢复其与 LDL-C的生理关系

2022-04-16

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

Front Pharmacol：不同PCSK9抑制剂，哪个降脂力量更强？

2022-08-06

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

AHA 2021丨MK-0616（一种口服PCSK9抑制剂）的临床安全性、药代动力学和降低低密度脂蛋白胆固醇的疗效

2022-03-05

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

JACC：高脂血症患者的福音！这些人能从强大的新型降脂药PCSK9抑制剂中获益！

2021-08-18

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

J Clin Med：一项初步研究：PCSK9抑制剂依洛尤单抗对心血管疾病高危患者醛固酮分泌的影响

2022-06-02

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

JAHA：动脉粥样硬化疾病患者PCSK9抑制剂使用情况

2021-09-12

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

防控有道，风险管理丨黄幸涛：早发冠心病患者的PCSK9i应用经验

2021-08-01

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

防控有道，风险管理丨廉羚：降脂唯“安”：PCSK9i改善椎动脉重度狭窄

2021-06-28

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

J INTERN MED：PCSK9与感染性休克患者死亡率相关

2020-07-25

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

专家访谈:生命至上——PCSK9抑制剂值得被更多ACS患者使用

2021-03-13

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

JAMA Cardiology：与他汀类药物和依折麦布相比，PCSK9抑制剂降低LDL-C的效果更显著

2021-08-01

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

JAHA：PCSK9抑制剂对其他降脂药物的使用情况的影响

2020-07-28

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

HFSA 2020：PCSK9抑制剂有效降低心脏移植后的胆固醇水平

2020-11-21

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

降脂神药！一年给药2次，药效持续17个月，诺华的siPCSK9疗法inclisiran获得欧洲CHMP的正面评价

2021-06-27

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

无论年龄和性别，诺华靶向PCSK9的siRNA疗法均可在17个月内持续有效降低LDL-C

2021-06-08

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

诺华与英国NHS联合，以快速推进胆固醇PCSK9的基因干扰药物inclisiran

2020-11-10

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

JAHA：PCSK9抑制剂可改善HIV携带者冠脉健康

2020-11-06

科室
- - 订阅+
  - 更多科室
工具
服务